Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00777595 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers
A Phase 1 study, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00777595: Completed Phase 1 study, sponsored by Chiesi Farmaceutici S.p.A..
NCT00777595 is a Phase 1 study that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 47 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00777595, a Phase 1 study, has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of single doses of therapeutic and supratherapeutic doses of inhaled CHF 4226 pMDI on ventricular repolarization in healthy subjects compared with placebo.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG CHF 4226 pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2008-10 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
What the finished NCT00777595 record still lists
NCT00777595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00777595 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00777595 about?
NCT00777595 is a clinical study titled "Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers". The purpose of this study is to evaluate the effect of single doses of therapeutic and supratherapeutic doses of inhaled CHF 4226 pMDI on ventricular repolarization in healthy subjects compared with placebo.
What is the current status of trial NCT00777595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2008-10. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00777595?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), CHF 4226 pMDI (DRUG).
Who is sponsoring clinical trial NCT00777595?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00777595's enrollment target sits among peer trials
47 1053rd of 2000 higher than 943 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia